D. E. Shaw & Co. Becomes 9.5% Owner, Backs Dilutive Restructuring Plan
GOSS sits 22% above its 52-week low of $0.14 on elevated volume (2.0× avg).
Summary
D. E. Shaw & Co. has become a 9.5% beneficial owner of Gossamer Bio by converting $30.29 million in existing debt to equity as part of the company's distressed debt exchange, agreeing to support critical dilutive measures for the company's survival.
Key Events · Ownership and Investor Activity · GOSS
-
D. E. Shaw & Co. Becomes 9.5% Owner
D. E. Shaw & Co. and its affiliated entities now beneficially own 46,485,295 Common Shares, representing 9.5% of Gossamer Bio's outstanding common stock.
-
Debt-to-Equity Conversion Completed
This ownership stake was acquired on June 4, 2026, as part of the early settlement of Gossamer Bio's distressed debt exchange. D. E. Shaw entities converted $30.29 million of existing convertible notes into new shares, new convertible notes, and purchase warrants.
-
Supports Critical Restructuring Proposals
D. E. Shaw has entered into a voting agreement to support shareholder proposals essential for the company's survival, including a massive increase in authorized shares (from 700M to 4B) and a reverse stock split (1-for-10 to 1-for-150).
-
Recent Share Dispositions
Between June 8-11, 2026, D. E. Shaw entities sold approximately 1.9 million shares for a total value of about $300,000, representing a minor adjustment to their overall position.
Analysis · GOSS · Life Sciences
This filing confirms that D. E. Shaw & Co. has become a significant 9.5% beneficial owner of Gossamer Bio. This ownership resulted from converting $30.29 million of existing convertible notes into new equity, new debt, and warrants as part of the company's distressed debt exchange. This is a critical step in Gossamer Bio's ongoing restructuring efforts to avoid bankruptcy and address Nasdaq compliance issues. D. E. Shaw's agreement to vote in favor of highly dilutive measures, including a substantial increase in authorized shares and a reverse stock split, signals institutional support for the company's survival plan, despite the significant dilution for existing shareholders.
At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.